The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 33, Issue 4, 2013, Pages 382-390

  Cho, Kyu Hyang ^a   Do, Jun Young ^a   Park, Jong Won ^a   Yoon, Kyung Woo ^a   Kim, Yong Lim ^b  

^a Yeungnam University College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Low GDP solution; Solute transport; Ultrafiltration

Indexed keywords

AQUAPORIN; CREATININE; GLUCOSE DEGRADATION PRODUCT; LACTIC ACID; SODIUM ION;

ARTICLE; BODY COMPOSITION; BODY WATER; CLINICAL PROTOCOL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE; EDEMA; FEMALE; GLUCOSE ABSORPTION; HUMAN; HYPOVOLEMIA; IMPEDANCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MESOTHELIUM CELL; OBESITY; OPEN STUDY; PERITONEUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SOLUTE; ULTRAFILTRATION; URINE VOLUME;

LOW-GDP SOLUTION; SOLUTE TRANSPORT; ULTRAFILTRATION;

ADULT; AGED; BIOLOGICAL TRANSPORT; BODY COMPOSITION; DIALYSIS SOLUTIONS; ELECTRIC IMPEDANCE; FEMALE; GLUCOSE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; ULTRAFILTRATION;

EID: 84880053262     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2011.00279     Document Type: Article

References (33)

1. Chaudhary K, Khanna R. Biocompatible peritoneal dialysis solutions: do we have one? Clin JAm Soc Nephrol 2010; 5:723-32.
2. Grodstein GP, Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564-7.
3. Leung JC, Chan LY, Tam KY, Tang SC, Lam MF, Cheng AS, et al. Regulation of CCN2/CTGF and related cytokines in cultured peritoneal cells under conditions simulating peritoneal dialysis. Nephrol Dial Transplant 2009; 24:458-69.
4. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61:570-8.
5. Washida N, Wakino S, Tonozuka Y, Homma K, Tokuyama H, Hara Y, et al. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant 2011; 26:2770-9.
6. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor β1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999; 19:221-30.
7. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. Am Soc Nephrol 2001; 12:2029-39.
8. Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int 2005; 25:415-25.
9. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
10. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25:248-55.
11. Fang W, Mullan R, Shah H, Mujais S, Bargman JM, Oreopoulos DG. Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Perit Dial Int 2008; 28:35-43.
12. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552-9.
13. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am JClin Nutr 1980; 33:27-39.
14. Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 2008; 28(Suppl 3):S117-22.
15. Bergström J, Heimbürger O, Lindholm B. Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? Perit Dial Int 1998; 18:467-73.
16. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S5-21.
17. Millar DJ, Holmes C, Faict D, Dawnay A. Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Adv Perit Dial 1998; 14:191-4.
18. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899-908.
19. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. Am Soc Nephrol 2000; 11:717-28.
20. Steinhauer HB, Schollmeyer P. Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 1986; 29:584-90.
21. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200-6.
22. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24:2909-14.
23. Davies SJ. Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009; 24:2620-2.
24. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424-9.
25. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007; 22:2038-44.
26. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
27. Konings CJ, Kooman JP, Gladziwa U, van der Sande FM, Leunissen KM. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67:1190-1.
28. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-63.
29. Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003; 23:381-90.
30. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. Am Soc Nephrol 2000; 11:729-39.
31. Pecoits-Filho R, Araújo MR, Lindholm B, Stenvinkel P, Abensur H, Romão JE Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17:1480-6.
32. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26:53-63.
33. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N on behalf of the Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3):S102-7.